Sign In
Last checked at 
12 May 2023 07:00
LEI: 549300Q7EXQQH6KF7Z84
12 May 2023
RTW Venture Fund Limited
Monthly Valuation Update & Factsheet
+13% NAV movement
RTW Venture Fund Limited (the "Company") announces that the unaudited net asset value attributable to the ordinary shares of the Company at the close of business on 30 April 2023 (the "NAV") was US$358.6 million, or US$1.69 per ordinary share, an increase of 13% from the previous month.
The monthly factsheet is available on the Company's website:
https://www.rtwfunds.com/rtw-venture-fund-ltd/factsheets-letters/
For Further Information:
RTW Investments, LP | +44 (0)20 7959 6361 |
Woody Stileman, Managing Director Krisha McCune, Director, Client Service |
|
|
|
Buchanan | +44 (0)20 7466 5107 |
Charles Ryland |
|
Henry Wilson |
|
George Beale |
|
|
|
Numis | +44 (0)20 7260 1000 |
Freddie Barnfield |
|
Nathan Brown |
|
Euan Brown |
|
| |
BofA Securities | +44 (0) 20 7628 1000 |
Edward Peel |
|
Kieran Millar |
|
| |
Elysium Fund Management Limited | +44 (0) 14 8181 0100 |
Joanna Duquemin Nicolle, Chief Executive Officer |
|
Sadie Morrison, Managing Director |
|
|
|
Morgan Stanley Fund Services USA LLC | +1 (914) 225 8885 |
About RTW Venture Fund Limited:
RTW Venture Fund Limited (LSE: RTW & RTWG) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Venture Fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.
RTW Venture Fund Limited is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.
Visit the RTW website at www.rtwfunds.com for more information.
Follow the stocks
